Supernus Pharmaceuticals v. Micro Labs: Trokendi XR Patent Suit Dismissed Without Prejudice
Supernus Pharmaceuticals filed suit in the District of New Jersey against Micro Labs Ltd. and Micro Labs USA, Inc., asserting 10 patents covering its Trokendi XR topiramate extended-release capsule franchise. The case was stipulated to dismissal without prejudice just 102 days after filing, with each party bearing its own costs.
A fast-resolved ANDA patent battle over topiramate ER formulations
On September 20, 2024, Supernus Pharmaceuticals, Inc. filed a patent infringement action in the U.S. District Court for the District of New Jersey against Micro Labs Ltd. and its U.S. subsidiary Micro Labs USA, Inc. The complaint asserted ten patents covering topiramate extended-release capsule formulations — the active pharmaceutical ingredient in Supernus’s branded product Trokendi XR, approved in 25 mg, 50 mg, 100 mg, and 200 mg dosage strengths. The suit was triggered by Micro Labs’s ANDA filing seeking FDA approval to market a generic version of Trokendi XR.
The case resolved through a stipulated dismissal without prejudice, entered by order of the court on December 31, 2024 — only 102 days after filing. Pursuant to Federal Rule of Civil Procedure 41, all claims, counterclaims, and defenses asserted by both Supernus and Micro Labs were dismissed without prejudice. Each party agreed to bear its own costs and attorneys’ fees. A dismissal without prejudice leaves the door open for Supernus to re-file if circumstances change — such as a shift in Micro Labs’s ANDA status or FDA approval.
The 102-day resolution is notably swift for a multi-patent ANDA case of this complexity — ten patents were asserted, suggesting the parties reached an accommodation before litigation could advance past early stages. The specific terms of any underlying commercial or licensing arrangement are not reflected in the public record. It is not known whether Micro Labs agreed to a market entry date, withdrew its ANDA, or whether a confidential settlement agreement was reached. The without-prejudice designation preserves Supernus’s ability to reassert these patents should Micro Labs reactivate its generic ambitions.
Filing to Dismissed without Prejudice in 102 days
102 days — resolved well below the median ANDA patent trial timeline
Dismissed without prejudice: what the stipulated exit means for both parties
Rule 41 stipulated dismissal without prejudice explained
Under Fed. R. Civ. P. 41, parties may jointly stipulate to dismiss an action. A dismissal without prejudice means no final judgment on the merits was entered — the litigation simply stops. Supernus retains the full right to re-file the same infringement claims against Micro Labs if it chooses. No court ruling resolved the validity, infringement, or enforceability of the ten asserted patents.
No merits adjudicatedSupernus preserves all optionality on its patent portfolio
Because the dismissal is without prejudice, Supernus’s ten topiramate ER patents remain intact and unchallenged by any court ruling. None of the asserted patents were invalidated or found non-infringed. Supernus can re-assert any or all of these patents against Micro Labs — or any other ANDA filer — in a future action. The public record does not disclose whether a licensing deal or market entry agreement was reached privately.
Patents survive; re-filing remains openMicro Labs exits without a validity win — and without market clearance
Micro Labs did not obtain a court ruling that its ANDA product is non-infringing or that Supernus’s patents are invalid. Without such a ruling, any commercial launch of its generic topiramate ER capsules would still carry patent risk. The 30-month stay triggered by the ANDA litigation may still apply depending on timing. Micro Labs bears no cost award but also has no declaratory judgment to support a launch.
No clearance ruling obtainedTrokendi XR exclusivity landscape remains contested
The quick, quiet resolution of a 10-patent ANDA case typically suggests a negotiated arrangement — whether a licensing deal, consent judgment with an agreed entry date, or ANDA withdrawal — though none is confirmed in the public record. For the topiramate ER sector, this outcome signals that Supernus’s patent thicket around Trokendi XR remains legally untested and potentially enforceable against other generic filers. Competitors monitoring this space should treat these patents as active enforcement risks.
Patent thicket remains intactFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Supernus Pharmaceuticals, Inc. | Company | Specialty CNS pharmaceutical company — holder of 10 Trokendi XR (topiramate ER) patentsSearch in Eureka ↗ |
| Defendant | Micro Labs | Individual | Generic pharmaceutical manufacturer and its U.S. subsidiary, ANDA applicant for topiramate ER capsulesSearch in Eureka ↗ |
| Co-Defendant | Micro Labs USA, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Alexander Lee Callo | Attorney | Counsel for Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Richard Frank Kurz | Attorney | Counsel for Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | William C. Baton | Attorney | Counsel for Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Haug Partners, LLP | Law Firm | Representing Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Saul Ewing, LLP | Law Firm | Representing Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | James S. Richter | Attorney | Counsel for Micro LabsSearch in Eureka ↗ |
| Defendant law firm | MIDLIGE RICHTER LLC | Law Firm | Representing Micro LabsSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulated order records a bilateral agreement to exit the litigation, with all claims, counterclaims, and defenses dismissed without prejudice under Rule 41. The explicit without-prejudice designation is legally significant: it forecloses any res judicata defence by Micro Labs in a subsequent action. The cost-bearing clause — each party its own fees — is consistent with a negotiated resolution rather than a unilateral capitulation, and suggests neither party conceded liability. No claim construction, validity finding, or infringement determination was made.
Supernus’s 10-patent Trokendi XR portfolio — topiramate extended-release formulations
The ten asserted patents — led by US8298576B2 and including US9622983B2, US8663683B2, US8877248B1, US8889191B2, US10314790B2, US8298580B2, US8992989B2, US9555004B2, and US9549940B2 — collectively form Supernus’s patent estate around Trokendi XR, an extended-release topiramate capsule formulation. The portfolio spans multiple application families filed across different periods, indicating a strategy of building overlapping claim coverage around formulation parameters, release kinetics, and therapeutic dosing. Topiramate is an anticonvulsant and migraine prophylaxis agent; the extended-release format is clinically differentiated from immediate-release formulations by improved tolerability and once-daily dosing.
From a competitive intelligence standpoint, a 10-patent estate asserted against a single ANDA applicant represents one of the more aggressive patent thicket strategies seen in CNS Hatch-Waxman litigation. Each patent in the portfolio potentially triggers its own 30-month regulatory stay, complicating generic entry timelines. The breadth of the portfolio — spanning multiple application numbers across nearly a decade of filings — suggests Supernus has deliberately layered continuations and divisionals to extend effective exclusivity. Any pharmaceutical company developing a generic topiramate ER product should conduct a thorough FTO analysis across all ten patents before advancing an ANDA filing.
Should your team run an FTO against Supernus’s Trokendi XR patent portfolio?
If your organisation is developing, formulating, or seeking regulatory approval for any topiramate extended-release capsule product, Supernus’s 10-patent portfolio represents a material IP risk that must be assessed before ANDA submission. The fact that this litigation closed without a single patent being invalidated or found non-infringed means there is no court-issued clearance that competitors can rely upon. Each of the ten patents remains a potential trigger for a new 30-month stay and fresh litigation.
PatSnap Eureka’s FTO Search Agent can map each of the ten asserted patents against your product’s formulation specifications, identify claim scope, flag prosecution history estoppel, and surface prior art candidates that could support an invalidity argument. The agent also tracks expiry dates across the full Trokendi XR portfolio so your regulatory and commercial teams can model earliest risk-free entry windows. Run a targeted FTO on this portfolio before your team advances formulation development or files an ANDA.
Run a freedom-to-operate analysis on US8298576B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman topiramate ER patent cases in U.S. district courts
Cases involving topiramate extended-release formulation patents and ANDA-triggered infringement actions in U.S. federal district courts, including the District of New Jersey.
What this case signals for the branded CNS generics IP landscape
A 10-patent ANDA case resolved in 102 days with no merits ruling carries clear signals for generic entry strategy and Hatch-Waxman risk management.
Without-prejudice exits in ANDA cases rarely mean the dispute is truly over
Dismissals without prejudice in Hatch-Waxman litigation frequently reflect confidential settlement or licensing arrangements — not capitulation. Supernus’s 10-patent portfolio around Trokendi XR remains fully enforceable, and the absence of a merits ruling means no invalidity precedent was set that other generics could rely upon.
10-patent assertion strategy signals Supernus’s defensive intent for Trokendi XR
Filing suit on ten patents simultaneously is a deliberate layering strategy designed to maximise the 30-month regulatory stay and increase the cost of litigation for any generic challenger. Companies developing topiramate ER generics should treat this portfolio as a serious enforcement barrier requiring comprehensive FTO analysis before ANDA submission.
Supernus v Micro — key questions answered
A dismissal without prejudice under Fed. R. Civ. P. 41 means no final judgment on the merits was entered. Supernus retains the right to re-file its infringement claims against Micro Labs. None of the ten asserted Trokendi XR patents were found invalid, unenforceable, or non-infringed. The dismissal does not constitute legal clearance for Micro Labs to launch its generic topiramate ER product.
Supernus asserted ten patents: US8298576B2, US9622983B2, US8663683B2, US8877248B1, US8889191B2, US10314790B2, US8298580B2, US8992989B2, US9555004B2, and US9549940B2. All ten cover aspects of topiramate extended-release capsule formulations corresponding to Trokendi XR (25 mg, 50 mg, 100 mg, and 200 mg). No merits ruling was issued on any of these patents.
The dismissal without prejudice does not grant Micro Labs legal clearance to market its generic topiramate ER product. Without a court ruling of non-infringement or invalidity, any commercial launch would still carry patent risk. The status of any applicable 30-month regulatory stay under Hatch-Waxman, and Micro Labs’s ANDA status with FDA, would govern the regulatory pathway to market.
The public record does not disclose the specific reason for the fast resolution. In Hatch-Waxman litigation, early dismissals without prejudice typically suggest a confidential settlement, licensing agreement, or market entry consent order — though none is confirmed here. The 102-day timeline indicates the parties reached an accommodation well before claim construction or any substantive motion practice.
Trokendi XR is Supernus Pharmaceuticals’ branded extended-release topiramate capsule, indicated for epilepsy and migraine prophylaxis. The 10-patent estate reflects a deliberate layering strategy common in branded pharma — using continuation and divisional applications to build overlapping claim coverage across formulation, release profile, and dosing parameters. This approach maximises the regulatory stay period under Hatch-Waxman and raises the cost of generic entry challenges.
PatSnap Eureka searches patents and litigation data to answer instantly.